A Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 combined with ezabenlimab in patients with small cell lung carcinoma and other neuroendocrine neoplasms expressing DLL3 (NCT05879978)
DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; LCNEC, large-cell neuroendocrine carcinoma; MTD, maximum tolerated dose; NEC, neuroendocrine carcinoma; OR, objective response; OS, overall survival; RECIST, Response Evaluation Criteria In Solid Tumors; SCLC, small-cell lung cancer; TcE, T-cell engager.